JeremiahBolesMD

Oncology • Raleigh, NC

Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Rex Hematology Oncology Associates

Join to view full profile

Dr. Boles is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boles' full profile

Already have an account?

Office
2901 Blue Ridge Rd
Ste 203
Raleigh, NC 27607
Phone+1 919-784-6818

Fax+1 919-784-6828

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2008 - 2011
University of North Carolina HospitalsResidency, Internal Medicine, 2005 - 2008
University of North Carolina at Chapel Hill School of MedicineClass of 2005

Certifications & Licensure

NC State Medical License 2005 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer Start of enrollment: 2013 Dec 01
Terminated
Phase 1, Phase 2
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer Start of enrollment: 2014 May 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
Hanna K Sanoff, Allison M Deal, Jai Patel, Jonathan D Sorah, Jacquelyne Gaddy
The Oncologist. 2024-09-06
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
Jonathan D Sorah, Allison M Deal, Sophia I Stein, Mattias Jonsson, Federico Innocenti
The Oncologist. 2024-09-06
32 citations
Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer.
Hanna K. Sanoff, Dominic H. Moon, Dominic T. Moore, Jeremiah C. Boles, Courtney Bui
Nanomedicine. 2019-06-01